keyword
MENU ▼
Read by QxMD icon Read
search

Peg-epo

keyword
https://www.readbyqxmd.com/read/25367412/preservation-of-anemia-control-and-weekly-esa-dosage-after-conversion-from-peg-epoetin-beta-to-darbepoetin-alfa-in-adult-hemodialysis-patients-the-transform-study
#1
MULTICENTER STUDY
Jan Donck, Lourdes Gonzalez-Tabares, Jacques Chanliau, Heike Martin, Kyriaki Stamatelou, Nick Manamley, Mourad Farouk, Janet Addison
INTRODUCTION: There is scant real-world information on switching treatment for anemia associated with chronic kidney disease (CKD) from methoxy polyethylene glycol-epoetin beta (PEG-Epo) to darbepoetin alfa (DA). TRANSFORM was a multi-center, observational study designed to describe the time course of hemoglobin (Hb) concentration (primary outcome measure) and other parameters of clinical management of anemia in European hemodialysis patients in clinical practice before and after a switch from PEG-Epo to DA...
November 2014: Advances in Therapy
https://www.readbyqxmd.com/read/24847351/regulation-of-hepcidin-25-by-short-and-long-acting-rhepo-may-be-dependent-on-ferritin-and-predict-the-response-to-rhepo-in-hemodialysis-patients
#2
Kazuya Takasawa, Naohisa Tomosugi, Chikako Takaeda, Teiryo Maeda, Norishi Ueda
BACKGROUND/AIMS: We examined whether regulation of hepcidin-25 by short- or long-acting recombinant human erythropoietin (rhEPO) is dependent on ferritin and predicts the response to rhEPO in hemodialysis (HD) patients. METHODS: Two studies with rhEPO were performed in 9 HD patients with a 2-year interval. Serum hepcidin-25 was measured at 0-18 h after intravenous epoetin-β (EPO) or methoxy polyethylene glycol-epoetin-β (PEG-EPO) administration and on days 3-7 after PEG-EPO...
January 2014: Nephron Extra
https://www.readbyqxmd.com/read/24173670/dose-conversion-ratio-in-hemodialysis-patients-switched-from-darbepoetin-alfa-to-peg-epoetin-beta-affirm-study
#3
MULTICENTER STUDY
Peter Choi, Mourad Farouk, Nick Manamley, Janet Addison
INTRODUCTION: There is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical studies. AFFIRM (Aranesp Efficiency Relative to Mircera) was a retrospective, multi-site, observational study designed to estimate the population mean maintenance dose conversion ratio [DCR; dose ratio achieving comparable hemoglobin level (Hb) between two evaluation periods] in European hemodialysis patients whose treatment was switched from DA to PEG-Epo...
November 2013: Advances in Therapy
https://www.readbyqxmd.com/read/22803621/between-subjects-variability-in-haemoglobin-and-dose-are-not-associated-with-the-erythropoiesis-stimulating-agent-used-to-treat-anaemia-in-dialysis-a-meta-analysis
#4
Juan José Pérez-Ruixo, Mercedes Cucala-Ramos, Ester García-Gonzalo, Beatriz Del Val Romero, Neus Valveny
AIMS: We aimed to compare mean and between subject variability in haemoglobin (Hb) and erythropoiesis-stimulating agents (ESA) dose across the ESA compounds used to treat anaemia in dialysis patients. METHODS: We performed a meta-analysis of randomized trials evaluating ESA in adult patients with chronic kidney disease on dialysis (target Hb 9-13.5 g dl(-1)), and compared mean Hb and its standard deviation (SD), and ESA dose and its coefficient of variation (CV) between the different agents [rHuEPO alfa or beta, darbepoetin alfa, pegylated-epoetin beta (PEG-EPO) or other epoetins]...
January 2013: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/22421952/use-of-methoxy-polyethylene-glycol-epoetin-beta-in-stage-3-4-or-5-non-dialysis-chronic-kidney-disease
#5
COMPARATIVE STUDY
Núria Padullés-Zamora, Dolors Comas-Sugrañes, M del Mar Pineda-Yuste, Ramon Jódar-Masanés, Alberto Martínez-Castelao
BACKGROUND: Methoxy polyethylene glycol-epoetin beta (PEG-EPO) is indicated for the treatment of anaemia due to chronic kidney disease. Its long half-life allows it to be administered once per month in maintenance therapy. OBJECTIVE: To evaluate the use, effectiveness and cost of PEG-EPO in a group of pre-dialysis chronic renal failure patients. METHOD: Retrospective observational study in pre-dialysis patients who began treatment with PEG-EPO between May 2008 and February 2009...
2012: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/20148243/doping-control-analysis-of-recombinant-human-erythropoietin-darbepoetin-alfa-and-methoxy-polyethylene-glycol-epoetin-beta-in-equine-plasma-by-nano-liquid-chromatography-tandem-mass-spectrometry
#6
Nola H Yu, Emmie N M Ho, Terence S M Wan, April S Y Wong
Recombinant human erythropoietin (rhEPO), darbepoetin alfa (DPO) and methoxy polyethylene glycol-epoetin beta (PEG-EPO) are synthetic analogues of the endogenous hormone erythropoietin (EPO). These erythropoiesis-stimulating agents have the ability to stimulate the production of red blood cells and are commercially available for the treatment of anaemia in humans. These drugs are understood to have performance-enhancing effects on human athletes due to their stimulation of red blood cell production, thereby improving delivery of oxygen to the muscle tissues...
April 2010: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/15784336/mixed-effects-modelling-of-the-interspecies-pharmacokinetic-scaling-of-pegylated-human-erythropoietin
#7
Koen Jolling, Juan Jose Perez Ruixo, Alex Hemeryck, An Vermeulen, Tony Greway
The aim of this study was to develop a population pharmacokinetic model for interspecies allometric scaling of pegylated r-HuEPO (PEG-EPO) pharmacokinetics to man. A total of 927 serum concentrations from 193 rats, 6 rabbits, 34 monkeys, and 9 dogs obtained after a single dose of PEG-EPO, administered by the i.v. (dose range: 12.5-550 microg/kg) and s.c. (dose range: 12.5-500 microg/kg) routes, were pooled in this analysis. An open two-compartment model with first-order absorption and lag time (Tlag) and linear elimination from the central compartment was fitted to the data using the NONMEM V software...
April 2005: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/15503315/population-pharmacokinetic-analysis-of-pegylated-human-erythropoietin-in-rats
#8
COMPARATIVE STUDY
Koen Jolling, Juan Jose Perez Ruixo, Alex Hemeryck, Vladimir Piotrovskij, Tony Greway
The purpose of this study was to model the pharmacokinetics of the pegylated human erythropoietin (PEG-EPO) after single-dose administration in rats, and to evaluate the influence of weight, sex, and pregnancy status on the pharmacokinetic parameters. A total of 436 serum concentrations from 193 Sprague-Dawley rats were obtained from four pharmacokinetic/toxicokinetic studies, in which a single dose of PEG-EPO was administered by the intravenous (i.v.; dose range: 2.5 to 500 microg/kg) and subcutaneous (s.c...
December 2004: Journal of Pharmaceutical Sciences
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"